A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways.

导出 OA

翻译打印收藏纠错

第一作者： Dayun,Yang

第一单位： Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350108, China; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian 350108, China.

作者： Dayun,Yang ^[1] ; Wensong,Luo ^[1] ; Jichuang,Wang ^[1] ; Min,Zheng ^[1] ; Xin-Hua,Liao ^[1] ; Nan,Zhang ^[1] ; Wenxian,Lu ^[1] ; Long,Wang ^[1] ; Ai-Zheng,Chen ^[2] ; Wen-Guo,Wu ^[2] ; Hekun,Liu ^[1] ; Shi-Bin,Wang ^[3] ; Xiao Zhen,Zhou ^[4] ; Kun Ping,Lu ^[5]

作者单位： Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350108, China; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian 350108, China. ^[1] Institute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen, Fujian 361021, China. ^[2] Institute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen, Fujian 361021, China. Electronic address: sbwang@hqu.edu.cn. ^[3] Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350108, China; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian 350108, China; Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address: xzhou@bidmc.harvard.edu. ^[4] Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350108, China; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian 350108, China; Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: klu@bidmc.harvard.edu. ^[5]

关键词 ATRA Controlled release Liver cancer Pin1 Supercritical carbon dioxide Targeted therapy